What Is Genuinely Working
Organic growth returned. Existing operations grew 2.2%, contributing €13.1M of revenue. Americas organic growth reached 6.7%, APAC 4.8%, and EMEA 0.3%. Interim Report pp. 27–29
Adjusted profitability improved. Adjusted EBITDA rose 1.0% to €141.8M and margin expanded from 23.9% to 24.5%. EMEA and APAC adjusted EBITDA grew 3.3% and 4.0%. Interim Report pp. 30–32
Debt moved in the right direction. Net financial debt excluding leases fell €30.8M from year-end to €1,014.6M; leverage improved from 1.92x to 1.84x. Interim Report pp. 7–8
Cash flow remained positive. Reported free cash flow was €17.8M and adjusted free cash flow was €23.6M, despite €21.0M of net capex. Presentation p. 9
Regional Scorecard
| Region | Reported | Organic | Adj. margin | View |
|---|---|---|---|---|
| EMEA | +0.1% | +0.3% | 30.3% | Margins lead |
| Americas | −8.6% | +6.7% | 23.3% | Mixed |
| APAC | +1.9% | +4.8% | 27.7% | Strongest |
Americas shows the reporting tension most clearly: strong underlying growth, but the managed-care exit and currency effects drove reported revenue sharply lower. Interim Report pp. 28–32
What The Headline Obscures
Reported results are still weak. Revenue fell 1.4%, EBITDA fell 6.3%, and reported group profit fell 68.0% to €10.5M. The operating recovery is visible mainly after adjustments. Interim Report pp. 6–7
The adjustment gap widened sharply. Adjusted group profit was €44.4M—€33.9M above reported profit. Adjustments included GN Hearing transaction costs, reorganization charges, UK disposal effects, and purchase-price amortization. Interim Report pp. 12–14
“Growth” excludes deliberate shrinkage. Organic growth was 2.2%, but Fit4Growth actions reduced revenue by 2.4% and FX reduced it another 2.2%, leaving reported revenue lower. Interim Report p. 27
GN Hearing changes the risk profile. The proposed €2.3B acquisition requires €1.7B cash plus 56M new shares. The cash facility is expected to be refinanced with debt and up to €0.75B of equity or equity-linked instruments; integration costs are estimated near €80M. Interim Report pp. 51–52
Corporate Language, Decoded
What To Watch Next
Bull case: Organic growth moves above management’s 3% full-year target, adjusted EBITDA margin improves by roughly 100 bps, and reported results begin closing the gap with adjusted measures. Interim Report p. 53
Bear case: EMEA remains sluggish, the US insurance decline offsets private-pay gains, and GN Hearing financing or integration costs keep reported earnings and leverage under pressure.
Measurable watchlist: Q2 organic growth versus 3%; Americas reported revenue and adjusted EBITDA; reported-to-adjusted profit gap; net debt before GN closing; final debt/equity mix, regulatory approval, and updated synergy/integration targets for GN Hearing.